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Calcium and vitamin D supplements reverse secondary hyperparathyroidism and are widely prescribed to prevent osteoporotic
fractures, with proven antifracture eﬃcacy when targeted to individuals with documented insuﬃciencies. Men who should
particularly be considered for calcium and vitamin D supplements include elderly or institutionalized individuals, patients with
documented osteoporosis on antiresorptive or anabolic medication, and individuals receiving glucocorticoids. Beneﬁts are most
apparentwhenadailydoseof1000–1200mgcalciumiscomplementedwith800IUvitaminD.Complianceisthekeytooptimizing
clinical eﬃcacy. While (conventionally dosed) vitamin D has not been associated with safety concerns, recent meta-analytic data
have provided evidence to suggest that calcium supplements (without coadministered vitamin D) may potentially be associated
with cardiovascular risks.
1.Introduction
Osteoporosis is a systemic skeletal disease characterized by
low bone mass and microarchitectural deterioration of bone
tissue, with a consequent increase in bone fragility [1].
Together with the age-related increase in the risk of falling,
this compromised bone strength results in an increased
fracture risk [2]. Key determinants of this age-related bone
fragility are calcium intake and levels of vitamin D, which
promotes intestinal calcium absorption [3]. In older individ-
uals, low dietary calcium intake and vitamin D deﬁciency are
common because of less sunlight exposure, reduced capacity
of the skin for vitamin D synthesis, inadequate vitamin
D dietary intake, or less eﬃcient intestinal absorption of
vitamin D, resulting in a negative calcium balance. This
stimulates the secretion of parathyroid hormone (PTH)
and induces age-associated secondary hyperparathyroidism,
which enhances bone turnover and accelerates bone loss [4].
Additionally, vitamin D deﬁciency leads to muscle weakness
andincreasestheriskoffalling[5],lowphysicalperformance
[6], and dynamic and postural instability [7].
Taken together, low serum calcium and vitamin D deﬁ-
ciency increase fracture risk by enhancing bone metabolism
as well as by increasing the risk of falling. Substitution with
calcium and vitamin D reduces both bone loss and the
risk of falling and is therefore recommended as ﬁrst-line
strategy in the prevention and treatment of osteoporosis
and osteoporotic fractures. Guidelines typically apply this
recommendation to both men and women, although most
individual trials and meta-analyses have only or mainly
included women, with limited data in men [8]. This paper
reviews the existing evidence for the eﬀect of calcium and
vitaminDsupplementationonbonemineraldensity(BMD),
muscle strength, and the risk of falls and fractures in men.2 Journal of Osteoporosis
2. Effect of CalciumandVitaminD on
Secondary Hyperparathyroidism,Bone
Mineral Density, and Bone Turnover
Both calcium and vitamin D supplements reverse the age-
associated secondary hyperparathyroidism in older individu-
als. This reduction in serum PTH is greater with combined
calcium and vitamin D supplementation than with vitamin
D alone [3] and depends on baseline calcium balance,
with the greatest eﬀect of supplementation observed in
individuals with the lowest calcium intake and/or vitamin
Dl e v e l s[ 9]. Gender, however, apparently is an independent
determinant of serum vitamin D [10] ,a n dt ok e e pP T H
within the normal range, women seem to require higher
levels of vitamin D than men [11].
A decrease in levels of PTH is associated with an increase
in BMD, as has been demonstrated in a recent meta-analysis
in more than 40000 men and women aged 50 years and older
[12]. In this meta-analysis of 24 trials reporting BMD as an
outcome, 19 trials included only women, while four trials
included men and women [13–16], and one trial included
only men [17]. Of the ﬁve trials that included men, two trials
determined the diﬀerence in bone loss between calcium in
monotherapy (±750mg per day) and placebo [13, 15], while
the others compared calcium (500mg to 1000mg per day)
plus vitamin D (500IU to 1000IU per day) with placebo
[14, 16, 17]. Overall, treatment with calcium plus vitamin
D or with calcium alone was associated with a signiﬁcantly
reduced rate of bone loss at the hip and spine. No subgroup
analyses were performed to evaluate the inﬂuence of sex
on treatment eﬀect on BMD, but in line with the overall
conclusion of this meta-analysis, reduced bone loss was seen
in most of the studies that included men [13–16]. However,
the one available men-only trial could not demonstrate a
reduction of bone loss in spite of supplementation with
1000mgcalciumand1000IUvitaminDperdayduringthree
years [17]. This negative result may reﬂect the high baseline
dietary calcium intake in the men included in the study
(1160mg per day) compared to lower doses of calcium in the
other trials, such as a daily dose of 700mg calcium [14]o r
less (550mg [15]), supporting the concept that substitution
therapy only makes sense when calcium balance is negative.
The decrease in PTH with calcium and vitamin D sup-
plementation is also associated with reduced bone turnover
[15, 16]. Meier et al. observed that calcium and vitamin D
supplementation during winter prevented seasonal changes
in PTH and bone loss in both men and women, although
the eﬀect on bone turnover was stronger in women. In this
context, it should be noted that seasonal changes of bone
turnover markers are only signiﬁcant in women and almost
absent in men [16].
3. Effect of CalciumandVitamin D on Muscle
Strength and the Risk of Falls
SupplementationwithcalciumandvitaminDnotonlyredu-
ces bone loss but also reduces the risk of falling by improving
muscle strength, muscle function, and balance [7, 18, 19].
Vitamin D receptors (VDRs) are present in skeletal muscle
cells and may account for these eﬀects [20, 21]. In a recent
meta-analysis, vitamin D therapy (200–1000IU per day)
lowered the risk of falling with 14% (RR 0.86, 95% CI 0.79–
0.93) compared with calcium or placebo [22]. In this meta-
analysisoftentrials,thenumberneededtotreatwithvitamin
D to prevent one fall was 15, and—although a dose of 800IU
vitamin D or greater was most eﬀective—a signiﬁcantly
lower fall risk was also seen with 400IU [22].
In an earlier meta-analysis of eight double blind ran-
domized controlled trials, on the other hand, a 19% fall
reduction (RR 0.81, 95% CI 0.71–0.92) was only observed
withadoseofatleast700IUvitaminDperdayanda23%fall
reduction (RR 0.77, 95% CI 0.65–0.90) with serum vitamin
D concentrations of at least 60nmol/L (24ng/mL), while less
than 700IU vitamin D per day did not reduce fall risk (RR
1.10,95%CI0.89–1.35)[23].Subgroupanalyseswereunable
to document a signiﬁcant reduction in falls in men but the
subset was small (N = 211) and the analyses underpowered.
In an earlier meta-analysis of the eﬀect of vitamin D on
falls, sex-speciﬁc subgroup analyses suggested that the fall-
preventing eﬀect of vitamin D is independent of sex: vitamin
D reduced the odds ratio of falling in men by 21% (OR
0.79, 95% CI 0.57–1.1; P = 0.17) and in women by 19%
(OR 0.81, 95% CI 0.65–1.00; P = 0.05). Again, the result of
the sex-speciﬁc subgroup analysis in men was not signiﬁcant
due to the small number of men in the included trials, but
numerically similar to the reduction seen in women [24].
Future research should determine the optimal dose of
vitamin D to prevent falls, but available evidence suggests
that men beneﬁt to a similar extent as women.
4. AntifractureEfﬁcacy of Calcium
andVitaminD
An e g a t i v ec a l c i u mb a l a n c ec o n t r i b u t e st of r a c t u r er i s k
by enhancing bone degradation through secondary hyper-
parathyroidism and by increasing the risk of falling through
an e g a t i v ee ﬀect on muscle strength, muscle function, and
balance. Substitution with calcium and vitamin D is there-
fore considered the ﬁrst-line strategy in the prevention of
osteoporotic fractures. To establish the antifracture eﬃcacy
of substitution, several individual trials and meta-analyses
have been performed with calcium or vitamin D alone or
combined calcium plus vitamin D.
4.1. Eﬀect of Calcium or Vitamin D Alone on Fracture Risk.
Meta-analyses comparing the eﬀect of calcium alone with
placebo showed that calcium in monotherapy does not
signiﬁcantly reduce fracture risk [25, 26]. Of these meta-
analyses, one included only women [25], while the other
included both genders and conducted sex-speciﬁc analyses
on the reduction of hip fracture risk [26]. Although data
in men were limited, this meta-analysis did not reveal a
diﬀerential eﬀe c to fc a l c i u mi nm e no rw o m e n :i nb o t hs e x e s
calcium in monotherapy was unable to reduce (hip) fracture
risk.Journal of Osteoporosis 3
T h es a m eh o l d st r u ef o rt h ee ﬀect of vitamin D alone
versus placebo: a meta-analysis of four randomized con-
trolled trials (N = 9083) showed that vitamin D alone was
insuﬃcient for fracture prevention, even when trials with
vitamin D used in higher dose (700–800IU per day) were
evaluated separately [27]. A more recent meta-analysis came
to the same conclusion: irrespective of sex, 400 to 800IU
v i t a m i nDa l o n ei sn om o r ee ﬀective in preventing fractures
than placebo [28].
These results should not come as a surprise because
the negative calcium balance in older and institutionalized
adults is often the result of insuﬃciencies in both calcium
and vitamin D. For example, community-dwelling French
women aged 75–90 years had a mean daily calcium intake
of just 569mg and 39% had a serum vitamin D less
than 30nmol/L (12ng/mL) [29]. In another trial, 66% of
institutionalized women had a daily calcium intake less than
800mg and a serum vitamin D less than 30nmol/L [30].
As a result, in these elderly and institutionalized individuals,
supplementation with calcium alone or vitamin D alone
would fail to restore calcium balance and prevent fractures
[8].
4.2. Eﬀect of Combined Calcium and Vitamin D Supplemen-
tation on Fracture Risk. A meta-analysis of six randomized
controlled trials (N = 45509) comparing the eﬀect of
combined calcium and vitamin D supplementation with
placebo [27] showed that this combination therapy, contrary
to calcium or vitamin D alone, signiﬁcantly reduced fracture
risk. The risk reduction was 12% for all nonvertebral
fractures, 18% for hip fractures, and 21% for hip fractures
when the one trial in this meta-analysis that did not use
700 to 800IU but 400IU vitamin D [31]w a se x c l u d e d .
Similarly, a recent Cochrane review found that calcium plus
vitaminDprev entedhipfracturesinfrailelderly[32]andthe
DIPART group concluded that the combination of calcium
and vitamin D signiﬁcantly reduced the risk of any fractures
and hip fractures and probably reduced the risk of clinical
vertebral fractures [28]. In their meta-analysis, the DIPART
group adjusted analyses for several factors including sex and
found that the risk reduction of combined calcium and
vitamin D was independent of sex [28].
Compared with vitamin D alone, combined calcium and
vitaminDsupplementationreducedtheriskforhipfractures
by 25% in an indirect comparison of meta-analyses [27].
This might be explained by the greater eﬀect of combined
calcium and vitamin D on secondary hyperparathyroidism
and bone loss [3]. In this context, it should be noted that
the only trial that directly compared the eﬀect of combined
calciumandvitaminDsupplementationwithvitaminD[33]
could not document a beneﬁcial eﬀect of the combination
therapy, but this study—like many individual trials in this
ﬁeld—suﬀered from a lack of statistical power, a lack of
targetingofthesupplementstoindividualswithdocumented
insuﬃciencies and a lack of compliance [27], which we will
discuss in more detail later.
Finally, one meta-analysis including 17 trials compared
the eﬀect of calcium plus vitamin D with calcium alone
on fractures [12]. Six of these trials included men and
women, 11 included only women, and there were no men-
onlytrials.CalciumorcalciumplusvitaminDwasassociated
with a 12% risk reduction in fractures of all types (RR
0.88, 95% CI 0.83–0.95). This treatment eﬀect was similar
across women and men, as suggested indirectly (since there
were no men-only trials) by the comparison of the women-
only to the mixed-sex trials. In this meta-analysis, subgroup
analyses showed that reduction in fracture risk was greater
in individuals with low dietary calcium intake (<700mg per
day) and in those with low serum vitamin D concentration
(<25nmol/L or <10ng/mL). Treatment eﬀect was most
eﬀective with at least 1200mg calcium and at least 800IU
of vitamin D. In this particular analysis, the combination
of calcium and vitamin D (RR 0.87, 95% CI 0.77–0.97)
and calcium in monotherapy (RR 0.90, 95% CI 0.80–1.00)
were equally eﬀective (P = 0.63) in the prevention of
osteoporotic fractures, a ﬁnding that is diﬃcult to reconcile
with evidence from other meta-analyses that calcium alone
does not signiﬁcantly reduce fracture risk [25, 26].
Overall, there is increasing evidence from several meta-
analyses for a beneﬁcial eﬀect of combined calcium and
v i t a m i nDs u p p l e m e n t a t i o no nf r a c t u r er i s kw i t hn oﬁ r m
reasons to assume that men would respond diﬀerently
from women. However, results of individual trials assessing
fracture reduction with combined calcium and vitamin
D supplementation have been inconsistent. Some of these
individuals trials, such as the Women’s Health Initiative
(WHI) trial [31] and the RECORD trial [33], failed to
demonstrate a signiﬁcant reduction in fracture risk, whereas
other trials found a beneﬁcial eﬀect of calcium and vitamin
D supplementation on fracture risk [14, 30, 34]. These
inconsistencies can be attributed to several factors, including
diﬀerences in targeting of the supplementation and diﬀer-
ences in compliance [8].
4.3. Determinants of Antifracture Eﬃcacy of Calcium and
Vitamin D Supplementation. To be eﬀective, supplementa-
tion with calcium and vitamin D has to be targeted to men
with documented or particularly at risk of calcium and/or
vitamin D insuﬃciencies, while general supplementation
in the community is not necessary. Except for extremely
minor subsets, baseline vitamin D status was not assessed
in participants of the WHI trial and the RECORD trial [31,
33]. In fact, most of these study participants were mobile,
healthy, and community-dwelling, who are less likely to have
vitamin D insuﬃciency and therefore less likely to beneﬁt
from substitution. This may have contributed signiﬁcantly
to the negative results of these studies [8]. Men who will
beneﬁt most from substitution therapy are older (>75 years
of age) or institutionalized persons in whom calcium and
vitamin D insuﬃciency is highly prevalent, as well as men
with documented osteoporosis or receiving glucocorticoids.
The addition of calcium and vitamin D to antiresorptive or
anabolic therapy in patients with established osteoporosis
is essential, given that calcium and vitamin D insuﬃciency
is common in patients with osteoporosis and osteoporosis
medication is most eﬀective in calcium and vitamin D4 Journal of Osteoporosis
replete individuals. Glucocorticoids suppress intestinal and
renal calcium absorption and increase urinary calcium
excretion, resulting in a negative calcium balance [35].
Therefore, patients on glucocorticoids are particularly prone
to fractures and supplementation therapy should be initiated
as soon as glucocorticoids are prescribed [3, 8]. Most meta-
analyses recommend a combination of 1000 to 1200mg
calcium with 700 to 800IU vitamin D per day [12, 27]o r
at least a dose in excess of 400IU (482–770IU) vitamin D
[36]. The aim is to increase serum levels of vitamin D to the
50–75nmol/L (20–30ng/mL) range [37, 38].
In addition to adequate targeting of supplementation,
compliance with calcium and vitamin D is critical as well,
to optimize clinical eﬃcacy. Within 6 weeks after calcium
and vitamin D have been discontinued, bone remodeling
resumes to pretreatment levels [39]. In line with these
ﬁndings, any positive eﬀects of calcium and vitamin D
on bone density will not persist after discontinuation of
the supplements [40]. Therefore, to prevent osteoporotic
fractures, compliance and persistence with calcium and
vitamin D are essential. However, even in relatively healthy
trial participants in studies like the WHI and the RECORD
trial, a signiﬁcant proportion of individuals did not comply
with supplementation: in both trials, estimated compliance
was only 40–60% [31, 33]. The negative outcome of these
trials can, at least partly, be explained by this lack of
compliance and emphasizes the importance of adherence to
treatment [8].
5. Safety Concerns about Supplementation
While (conventionally dosed) vitamin D has not been
associated with safety concerns, a recent meta-analysis has
provided evidence to suggest that calcium supplements
(without coadministered vitamin D) may potentially be
associated with cardiovascular risks. This safety concern may
p o t e n t i a l l yb ee v e nm o r eo fa ni s s u ei nm e nt h a ni nw o m e n .
However,inthemeta-analysis,sex-speciﬁcsubgroupanalysis
showed this elevated cardiovascular risk to be independent
of sex [41]. Although these ﬁndings constitute a safety
signal that has to be taken seriously, the data have to be
interpreted with some caution. When dietary intake was
taken into account, there was no signiﬁcant correlation
between calcium intake and risk of infarction. In addition,
there was no eﬀect of calcium on strokes or death, none
of the trials had adjudicated cardiovascular outcomes in
a standardized manner, and the statistical outcome was
only borderline signiﬁcant. Finally, there are numerous large
studies of calcium plus vitamin D that have shown no
increased risk of cardiovascular events [31, 42] and studies
of calcium alone that did not provide evidence of an
increased cardiovascular risk with daily supplemental intake
of 1200mg calcium in women [43] or 1000mg calcium in
men [44]. Nevertheless, reassessment of the role of calcium
supplements to prevent osteoporotic fractures is warranted.
Because, in general, men are more at risk of heart disease
thanwomen,futurestudieswithsupplementsshouldinclude
cardiovascular endpoints and carefully assess safety in men.
6. Conclusion
Age-associated bone loss due to secondary hyperparathy-
roidism and an increased risk of falling are key determinants
of osteoporosis and osteoporotic fractures. Substitution with
calcium and vitamin D reduces bone loss by reversing sec-
ondaryhyperparathyroidismandpreventsfallsbyimproving
muscle strength, muscle function, and balance. As a result,
calcium and vitamin D supplementation is generally recom-
mended in the prevention of osteoporotic fractures. In men,
data on the eﬀect of calcium and vitamin D supplements on
BMD and the risk of falls and fractures are limited. However,
from the mechanism of bone loss and from the available evi-
dence, there is no reason to assume that men would respond
diﬀerently to calcium and vitamin D supplementation
compared to women. Combined supplementation with 1000
to 1200mg calcium and 800IU vitamin D per day should
be particularly considered in older or institutionalized men,
men receiving glucocorticoids, and in male osteoporosis
patients on antiresorptive or anabolic medication.
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